Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants

Executive Summary

• Hemostemix highlights a research article published in the journal Cells on June 29, 2025, detailing how its proprietary autologous cell therapies (ACP-01 and NCP-01) may improve the longevity and performance of Brain-Computer Interfaces (BCIs).
• The study proposes using patient-derived Angiogenic Cell Precursors (ACP-01) and Neural Cell Precursors (NCP-01) to mitigate inflammation, scarring, and apoptosis at BCI implant sites, potentially extending device lifespan from months to years.
• The Company is actively pursuing licensing agreements with BCI technology companies to integrate these cell therapies, with management indicating that further news regarding potential partners is expected.

Key Details

• Publication Details: The research was authored by Fraser C. Henderson Sr. and Kelly Tuchman and published in the journal Cells on June 29, 2025.
• Problem Addressed: Implantable BCI electrodes often fail between six months and one year due to inflammation, scarring, and programmed cell death (apoptosis).
• Proposed Solution: Delivery of two types of autologous progenitor cells into the cerebrospinal fluid:
  • ACP-01 (VesCell™): Produces signals (IL-8, VEGF, angiogenin) to attract Natural Killer (NK) cells, suppress inflammation, reduce scarring, and support angiogenesis. It also recruits peripheral CD34+ precursor cells.
  • NCP-01: Expresses receptors (CXCR4) to migrate to the BCI site, shifting immune cells to a neuroprotective (M2) state and differentiating into neurons/glial cells to promote synaptic connections and neural plasticity.
• Mechanism of Action:
  • Activation of neurotrophic factors and NF-κB pathways to protect cells (anti-apoptosis).
  • Promotion of synaptogenesis and neuritogenesis to improve learning-related plasticity.
  • Decreased inflammation and increased neuro-protectiveness at the implant site.
• Strategic Outlook: Hemostemix aims to license ACP-01 and NCP-01 to BCI companies. CEO Thomas Smeenk stated that shareholders can expect more news as the Chief Commercialization Officer and CEO meet with potential partners.
• Company Background: Hemostemix has completed seven clinical studies with 318 subjects and published results in 11 peer-reviewed publications. ACP-01 is noted for safety and statistical significance in treating conditions such as peripheral arterial disease and chronic limb-threatening ischemia.

Notable Quotes

• "We imagine a world where the environment for BCI, the patient's brain, augmented by the patients' own stem cells, improves the longevity of the implants from months to a lifetime, improves signal fidelity to increase functional movement, and increases learning and memory retention," stated Dr. Fraser Henderson, lead author.
• "I want to thank Dr. Henderson and Ms. Tuchman for this very thorough exposition of the benefits of using one's own DNA structured as ACP & NCP to improve BCIs. Truly, this is incredible work. Coupled with our market analyses of the top three BCI companies, shareholders can expect more news to follow, as Mr. Lawrence, Chief Commercialization Officer and I meet with potential partners," stated Thomas Smeenk, CEO.